Ebglyss Approved in Saudi Arabia – A New Hope for Moderate to Severe Atopic Dermatitis

0 SAR
Checkout

Overview

We are excited to announce that Ebglyss (Lebrikizumab) is now approved in Saudi Arabia for the treatment of patients with moderate to severe Atopic Dermatitis (AD) aged 12 and above. With its unique IL-13 inhibition mechanism, Ebglyss Starts Strong, Lasts Long, and is Maintained Monthly, along with a favorable safety profile proven in clinical trials.

This Class for

  • Physician
  • Resident / Fellow

What I will learn?

  • Enhance awareness and clinical understanding among targeted healthcare professionals regarding Atopic Dermatitis (AD) and the differentiated role of Ebglyss (lebrikizumab) in the management of moderate-to-severe AD.

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
    Please go to PDF Material for prescribing information.

    PP-LK-SA-0108

Related Classes